摘要
2019年末,在中国出现新型冠状病毒(SARS-CoV-2)感染疾病,疫情的发展引起世界关注。中国举国上下一直将防控疫情、保卫人民生命安全作为全党全国的第一要务。对病毒性疾病预防用疫苗和治疗用药物是重要组成部分,认识这类药物的研发难点,才有利于抗病毒药物研发。综述对SARS-CoV-2的认识、反映中国科学家对新冠病毒肺炎的基础研究贡献,探讨符合国家和国际技术规范的抗病毒药物研发策略、药物的筛选和研发及成药性评价研究思路。
China’s novel coronavirus(2019-nCoV)infection has attracted worldwide attention since the end of 2019.China has made the prevention and control of the epidemic and the protection of people’s lives the top priority of the party and the country.Vaccines for the prevention of viral diseases and drugs for treatment are important components.Understanding the difficulties in the development of these drugs is conducive to the development of antiviral drugs.This article reviews is the understanding the coronavirus(SARS-CoV-2),reflecting the contribution of Chinese scientists to the basic research of pneumonia,and discussing the development,screening and evaluation of antiviral drugs in line with national and international technical specifications.
作者
刘昌孝
伊秀林
王玉丽
闫凤英
LIU Changxiao;YI Xiulin;WANG Yuli;YAN Fengying(Drug Evaluation and Research Center,Tianjin Institute of Pharmaceutical Research,Tianjin 300462,China;Biotechnology research center,Tianjin Institute of Pharmaceutical Research,Tianjin 300462,China;Modern Chinese Medicine Research Center,Tianjin Institute of Pharmaceutical Research,Tianjin 300462,China;Tianjin Binhai Research Center for Food and Drug Regulatory Science,Tianjin 300462,China;School of Chemical Engineering,Tianjin University,Tianjin 300072,China)
出处
《药物评价研究》
CAS
2020年第3期361-371,共11页
Drug Evaluation Research
关键词
新型冠状病毒
肺炎
抗病毒新药
生物信息学
抗病毒新药筛选
成药性
研发策略
novel coronavirus
pneumonia
antiviral drug
bioinformatics
new drug screening
druggability
research and development strategy
